` CADL (Candel Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

CADL
vs
S&P 500

Over the past 12 months, CADL has underperformed S&P 500, delivering a return of -19% compared to the S&P 500's 9% growth.

Stocks Performance
CADL vs S&P 500

Loading
CADL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CADL vs S&P 500

Loading
CADL
S&P 500
Difference
www.alphaspread.com

Performance By Year
CADL vs S&P 500

Loading
CADL
S&P 500
Add Stock

Competitors Performance
Candel Therapeutics Inc vs Peers

S&P 500
CADL
ABBV
AMGN
GILD
VRTX
Add Stock

Candel Therapeutics Inc
Glance View

Market Cap
242.3m USD
Industry
Biotechnology

Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The company is headquartered in Needham, Massachusetts and currently employs 50 full-time employees. The company went IPO on 2021-07-27. The firm is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The firm also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.

CADL Intrinsic Value
Not Available
Back to Top